Abstract:Zhichao Lin, 1, &ast Wenhai Huang, 1, &ast Yongsheng Yi, 1, &ast Dongbing Li, 2, &ast Zehua Xie, 1 Zumei Li, 1 Min Ye 1 1 Department of Thoracic Surgery, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, 529030, Guangdong, People's Republic of China; 2 MyGene Diagnostics Co., Ltd., Guangzhou, 510000, Guangdong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhichao Lin; Min Ye Department of Thoracic Surgery, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, No. 23 Haibang Street, Beijie, Jiangmen, 529030, Guangdong, People's Republic of China Tel +86-750-3989432 Email ; Background: The role of long noncoding RNA (LncRNA) ADAMTS9 antisense RNA 2 (ADAMTS9-AS2) is unclear in lung adenocarcinoma (LUAD). The aim of this study was to explore the relationship between ADAMTS9-AS2 and LUAD, based on The Cancer Genome Atlas (TCGA) database and bioinformatics analysis. Methods: Various statistical methods, Kaplan–Meier method, Cox regression analysis, GSEA, and immune infiltration analysis were used to evaluate the relationship between clinical features and ADAMTS9-AS2 expression, prognostic factors, and the significant involvement of ADAMTS9-AS2 in function. Results: In LUAD patients, low expression of ADAMTS9-AS2 was associated with N stage (P=0.011), gender (P=0.002), number of packs smoked (P=0.024) and smoker (P< 0.001). Low ADAMTS9-AS2 expression predicted a poorer overall survival (OS) (HR: 0.68; 95% CI: 0.51– 0.91; P=0.01). And ADAMTS9-AS2 expression (HR: 0.626; 95% CI: 0.397– 0.986; P=0.043) was independently correlated with OS in LUAD patients. Unwinding of DNA, extrinsic pathway, polo-like kinase-mediated events, cori cycle, MCM pathway, proteasome pathway, lagging strand synthesis and PCNA-dependent long patch base excision repair were differentially enriched in ADAMTS9-AS2 high expression phenotype. ADAMTS9-AS2 expression was correlated with certain immune infiltrating cells. Conclusion: In LUAD patients, ADAMTS9-AS2 expression was significantly associated with poor survival and immune infiltration. ADAMTS9-AS2 may be a promising biomarker of prognosis and response to immunotherapy for LUAD. Keywords: lung adenocarcinoma, ADAMTS9-AS2 antisense RNA 2, prognosis, immune infiltration, biomarker Lung cancer is the leading cause of cancer death worldwide. 1 Lung adenocarcinoma (LUAD) is one of the histological types, accounting for about half of all lung cancers. 2 Despite advances in new targeted therapies, chemotherapy, radiotherapy and surgical approaches, the 5-year survival rate for LUAD is only 20%. 3 Identifying the underlying molecular mechanisms and important prognostic biomarkers of LUAD is crucial. Long noncoding RNAs (lncRNAs) longer than 200 bp can interact with mRNAs, miRNAs, and circulating RNAs to participate in a complex network of gene expression regulation. 4 Insights into the function of a few characteristic lncRNAs suggested a surprising diversity of cellular processes, from chromatin modification, transcription, splicing, and translation to cell differentiation, cell cycle regulation, and stem cell reprogramming. 5 lncRNAs are involved in the development of some cancers. 6 Aberrant lncRNAs are involved in the development and progression of LUAD. 7–10 Therefore, screening for lncRNAs clinically relevant to LUAD is important for the diagnosis and treatment of LUAD. ADAMTS9-AS2 and CADM2 expression were independent prognosis indicators in esophageal squamous cell carcinoma (ESCC) patients. 11 ADAMTS9-AS2 could be a potential biomarker for patients with bladder cancer (BC). 12 ADAMTS9-AS2 is a potential diagnostic and prognostic marker for prostate cancer (PCa). 13 ADAMTS9-AS2 was significantly downregulated in LUAD. 14 ADAMTS9-AS2 functions as a tumor suppressor in LUAD. 15 Upregulation of lncRNA ADAMTS9-AS2 inhibits lung cancer progression by suppressing miR-223-3p and promoting TGFBR3. 16 However, the correlation between ADAMTS9-AS2 and clinical characteristics of LUAD patients and immune infiltration has not been studied. In this study, the correlation between ADAMTS9-AS2 expression levels and clinical features of LUAD was explored based on the Cancer Genome Atlas (TCGA) database and LUAD RNA-seq data in GTEx, comparing the difference in ADAMTS9-AS2 expression between tumor tissues and normal samples. The prognostic value of ADAMTS9-AS2 in LUAD was assessed. Through genomic enrichmen -Abstract Truncated-

Upregulation of the tumor suppressor gene LIN9 enhances tumorigenesis and predicts poor prognosis of lung adenocarcinoma

LINC00941 Promotes Cell Malignant Behavior and Is One of Five Costimulatory Molecule-Related lncRNAs That Predict Prognosis in Renal Clear Cell Carcinoma

Integrated Bioinformatics Analysis Reveals Correlations of High TRIM59 Expression with Worse Prognosis and Immune Infiltrates in Lung Adenocarcinoma

Study of LY9 as a potential biomarker for prognosis and prediction of immunotherapy efficacy in lung adenocarcinoma

CLEC10A is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in lung adenocarcinoma

Loss of LIMCH1 Predicts Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics

Characterizing Tumor Microenvironment and Risk Genes in Lung Adenocarcinoma through scRNA-seq and Bulk RNA-seq Data

LncRNA ADAMTS9-AS2 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma

Pan-cancer Analysis of LINC02535 As a Potential Biomarker and Its Oncogenic Role in Lung Adenocarcinoma

Downregulated Expression of CLEC9A as Novel Biomarkers for Lung Adenocarcinoma

Role and mechanism of LINC02390 and its potential target genes, CLECL1 and CD69, in immune microenvironment of lung adenocarcinoma

Linc00152 Promotes Cancer Cell Proliferation and Invasion and Predicts Poor Prognosis in Lung Adenocarcinoma

High Expression of Transcriptional Factor HoxB9 Predicts Poor Prognosis in Patients with Lung Adenocarcinoma.

Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches

A Novel Lncrna, LUADT1, Promotes Lung Adenocarcinoma Proliferation Via the Epigenetic Suppression of P27

Low expression of LINC00982 and PRDM16 is associated with altered gene expression, damaged pathways and poor survival in lung adenocarcinoma.

LINC00628 is Differentially Expressed Between Lung Adenocarcinoma and Squamous Cell Carcinoma and is Associated with the Prognosis of NSCLC

Prognostic characteristics of T-cell mediated cell killing-related genes in lung adenocarcinoma

An Inflammation-Related Nine-Gene Signature to Improve Prognosis Prediction of Lung Adenocarcinoma

DNASE1L3 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma Based on Data Mining

The Expression, Significance And Function Of Cancer Susceptibility Candidate 9 In Lung Squamous Cell Carcinoma: A Bioinformatics And In Vitro Investigation